BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29846633)

  • 1. Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.
    Marlow LA; Rohl SD; Miller JL; Knauf JA; Fagin JA; Ryder M; Milosevic D; Netzel BC; Grebe SK; Reddi HV; Smallridge RC; Copland JA
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3169-3182. PubMed ID: 29846633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
    Liu D; Liu Z; Condouris S; Xing M
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2264-71. PubMed ID: 17374713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.
    Mitsutake N; Knauf JA; Mitsutake S; Mesa C; Zhang L; Fagin JA
    Cancer Res; 2005 Mar; 65(6):2465-73. PubMed ID: 15781663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonally related but phenotypically divergent human cancer cell lines derived from a single follicular thyroid cancer recurrence (TT2609).
    Geldof AA; Versteegh LRT ; van Mourik JC; Rooimans MA; Arwert F; Hermsen MA; Schadee-Eestermans IL; van Dongen GA; van der Valk P; van der Clement EHP ; Lips P; Teule GJ
    Thyroid; 2001 Oct; 11(10):909-17. PubMed ID: 11716037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
    Meireles AM; Preto A; Rocha AS; Rebocho AP; Máximo V; Pereira-Castro I; Moreira S; Feijão T; Botelho T; Marques R; Trovisco V; Cirnes L; Alves C; Velho S; Soares P; Sobrinho-Simões M
    Thyroid; 2007 Aug; 17(8):707-15. PubMed ID: 17725429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
    Liu D; Liu Z; Jiang D; Dackiw AP; Xing M
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4686-95. PubMed ID: 17911174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines.
    Gretarsson S; Nygren A; Rosendahl AH; Mylona N; Kjellén E; Jin Y; Paulsson K; Borg Å; Brun E; Tennvall J; Bergenfelz A; Greiff L; Wennerberg J; Ekblad L
    Acta Otolaryngol; 2020 Apr; 140(4):337-343. PubMed ID: 31922436
    [No Abstract]   [Full Text] [Related]  

  • 11. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
    Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
    Loukopoulos P; Kanetaka K; Takamura M; Shibata T; Sakamoto M; Hirohashi S
    Pancreas; 2004 Oct; 29(3):193-203. PubMed ID: 15367885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
    Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
    Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.
    Morrison JA; Pike LA; Lund G; Zhou Q; Kessler BE; Bauerle KT; Sams SB; Haugen BR; Schweppe RE
    Horm Cancer; 2015 Jun; 6(2-3):87-99. PubMed ID: 25800363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
    Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
    Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
    Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
    Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.